The health and safety of our employees, patients, customers and communities is our top priority. Read about our response to COVID-19

Inspire Medical Systems, Inc. Announces Medicare Policy Release Date of Local Coverage Determination for Sole Remaining Region

Download as PDF

MINNEAPOLIS, Minnesota – May 11, 2020 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical
technology company focused on the development and commercialization of innovative and minimally invasive
solutions for patients with obstructive sleep apnea (“OSA”), announced today that Palmetto GBA, LLC, (“Palmetto”)
has announced the release date of June 21, 2020, for its final Local Coverage Decision (“LCD”) policy covering
Inspire therapy. Palmetto was the only remaining Medicare Administrative Contractor (“MAC”) to have not either
issued its final LCD policy or set a release date.

Palmetto covers Medicare-aged individuals in Alabama, Georgia, North Carolina, South Carolina, Tennessee,
Virginia, and West Virginia. In addition to Palmetto, Inspire recently announced that Wisconsin Physicians Services
(“WPS”) Government Health Administrators issued the effective date of June 14, 2020 for its final LCD. WPS
covers Medicare patients in Indiana, Iowa, Kansas, Michigan, Missouri, and Nebraska.

“We are excited to announce that once the final LCDs from Palmetto and WPS are issued, Inspire therapy will have
Medicare coverage across the entire United States,” said Tim Herbert, President and Chief Executive Officer of
Inspire Medical Systems. “This is a significant milestone for Inspire and an important advancement for the
Medicare-aged population, as this has the potential to enhance their access to Inspire therapy. We believe that the
swift and uniform manner in which the seven MACs have issued consistent LCDs to cover the entire U.S. Medicare-
aged population supports Inspire therapy’s potential to significantly benefit patient outcomes. Importantly, all of the
policies became, or will become, effective during the COVD-19 pandemic and we anticipate that these LCDs
position us well to further accelerate growth once the impact of COVID-19 subsides.”

The seven Medicare policies state that U.S. Food and Drug Administration-approved hypoglossal nerve
neurostimulation is considered medically reasonable and necessary for the treatment of moderate to severe OSA
when certain criteria are met. There are approximately 40 million Medicare-aged patients, and an additional 20
million lives covered under commercial Medicare plans, known as Medicare Advantage.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of innovative and
minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first
and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to
severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements,
including, without limitation, statements regarding the expected growth in our business following the impact of
COVID-19 and improvements in market access. In some cases, you can identify forward-looking statements by
terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,”
‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative
of these terms or other similar expressions, although not all forward-looking statements contain these words.

These forward-looking statements are based on management’s current expectations and involve known and
unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable
market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations,
financial position, research and development costs, capital requirements and our needs for additional financing;
commercial success and market acceptance of our Inspire therapy; the impact of the ongoing and global COVID-19
pandemic; general and international economic, political, and other risks, including currency and stock market
fluctuations and the uncertain economic environment; our ability to achieve and maintain adequate levels of
coverage or reimbursement for our Inspire system or any future products we may seek to commercialize;
competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our
indications and develop and commercialize additional products; our business model and strategic plans for our
products, technologies and business, including our implementation thereof; our ability to accurately forecast
customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers,
contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand,
manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in
markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our
ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our
senior management and other highly qualified personnel; risk of product liability claims; risks related to information
technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or
obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or
obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare
industry generally, including healthcare reform measures in the U.S. and international markets; the timing or
likelihood of regulatory filings and approvals; risks related to our debt and capital structure; our ability to establish
and maintain intellectual property protection for our Inspire therapy and system or avoid claims of infringement; tax
risks; risks that we may be deemed an investment company under the Investment Company Act of 1940; regulatory
risks; risks related to our ceasing to qualify as a smaller reporting company or an emerging growth company; the
volatility of the trading price of our common stock; and our expectations about market trends. Other important
factors that could cause actual results, performance or achievements to differ materially from those contemplated in
this press release can be found under the captions “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2019, as updated in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and
as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the
SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other
important factors could cause actual results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking statements represent management’s estimates as
of the date of this press release. While we may elect to update such forward-looking statements at some point in the
future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our
views to change. Thus, one should not assume that our silence over time means that actual events are bearing out
as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the date of this press release.

Investor & Media Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com